- Denosumab 70mg in 1ml (120mg) vial is approved for the prevention of skeletal-related events in adults with bone metastases from solid tumours in line with NICE
- Note: denosumab is not approved for therapy induced bone loss in non- metastatic prostate cancer (NICE).
- North Cumbria only
- New patients

- Exisiting patients

|